Grail Stock Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test
Key Points:
- Investor’s Business Daily provides information solely for informational and educational purposes and does not offer investment advice or recommendations.
- The data presented is sourced from what is believed to be reliable providers, but accuracy, timeliness, and suitability are not guaranteed.
- Past investment performance is not indicative of future results, and authors may hold positions in the stocks they discuss.
- Real-time pricing is provided by Nasdaq Last Sale, with ownership and estimate data from LSEG and FactSet, but not all markets are covered.
- The content and trademarks are the property of Investor’s Business Daily, LLC, and information is subject to change without prior notice.